logo
Hibakusha from Nagasaki picked for U.N. panel on nuke war effects

Hibakusha from Nagasaki picked for U.N. panel on nuke war effects

Asahi Shimbun22-07-2025
An atomic bomb survivor who is a doctor with experience treating other hibakusha and conducting leukemia research has been appointed to a new United Nations panel that examines the effects of nuclear war.
'Hiroshima and Nagasaki are real cities against which nuclear weapons were directly used, and Japanese researchers know the impact of nuclear weapons in totality,' said Masao Tomonaga, emeritus director of the Japanese Red Cross Nagasaki Atomic Bomb (Genbaku) Hospital.
He is among the 21 members of the Scientific Panel on the Effects of Nuclear War announced by U.N. Secretary-General Antonio Guterres on July 17.
The formation of the independent panel is 'a response to a global environment in which the risk of nuclear war is higher than at any point since the depths of the Cold War,' according to the United Nations.
Tomonaga, 82, became a hematologist after graduating from Nagasaki University's School of Medicine.
He expressed his eagerness to work on the international panel, saying there is a need to scientifically clarify what would occur in the event of a nuclear war.
'It is an honor to be selected as a researcher of atomic bombings,' the Nagasaki native said. 'I would like to speak about experiences in Nagasaki and Hiroshima, including developments over the (last) 80 years.'
The panel was established in accordance with a U.N. General Assembly resolution adopted in December.
It is tasked with examining 'the physical effects and societal consequences' of a nuclear war, and 'their impacts on public health, global socioeconomic systems, agriculture and ecosystems,' according to a U.N. statement.
The panel is expected to hold its first meeting in September and submit its final report to the U.N. General Assembly session in 2027.
(This article was written by Kyota Tanaka and Takashi Ogawa.)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Survey in Japan Finds Majority of People Sleep with AC on in Summer

time10 hours ago

Survey in Japan Finds Majority of People Sleep with AC on in Summer

Japan Data Lifestyle Health Aug 7, 2025 In Japan's hot summers, more than half of people leave the air conditioner on through the night. A survey in Japan found that 92.5% of the respondents have an air conditioner in their home, and that 38.1% of them always turn it off when going out during the summer. The survey was conducted by market research firm Cross Marketing, targeting people nationwide aged 20 to 69, with a total of 1,100 valid responses received. Among those surveyed, 56.4% said that they leave their air conditioner on throughout the night. All age groups were above 50%, with especially high rates among those in their twenties and thirties, at 59.0% and 58.2%, respectively. With Japan continuing to face severe heatwaves every summer, the habit of cooling down a room even when outside the home or asleep is becoming the norm among more and more people. According to the survey results, the most common temperature setting is between 26.0 ° and 27.5 ° Celsius during the day, and between 27.0 ° and 28.5 ° at night. Data Sources (Translated from Japanese. Banner photo © Pixta.) summer heatstroke

Japan OKs Price Cut for Alzheimer's Drug Lecanemab

time13 hours ago

Japan OKs Price Cut for Alzheimer's Drug Lecanemab

News from Japan Aug 6, 2025 20:15 (JST) Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and U.S. industry peer Biogen Inc., by 15 pct in Japan starting Nov. 1. The decision is based on an assessment by the Central Social Insurance Medical Council that cited the low cost-effectiveness of the drug used to treat dementia caused by Alzheimer's disease. The price of the drug will be lowered to 97,277 yen for a 500-milligram bottle. Dosages are based on weight. For example, a patient weighing 50 kilograms would see an annual cost reduction from about 2.98 million yen to about 2.53 million yen. Lecanemab is said to be innovative because it removes abnormal proteins that accumulate in patients' brains, and is expected to slow the progression of the disease. The medication was subject to a system that adjusts drug prices based on cost-effectiveness for high-priced or large-market drugs. [Copyright The Jiji Press, Ltd.] Jiji Press

Sumitomo Pharma files for approval of stem cell Parkinson's treatment
Sumitomo Pharma files for approval of stem cell Parkinson's treatment

Nikkei Asia

timea day ago

  • Nikkei Asia

Sumitomo Pharma files for approval of stem cell Parkinson's treatment

Induced pluripotent stem cell technology was developed in Japan in 2007, but progress on developing treatments for diseases has been slow. (Photo obtained by Nikkei) NANAKO TAKEUCHI, YUKI MISUMI and AKANE ASAMI OSAKA/TOKYO -- Japanese drugmaker Sumitomo Pharma has applied for approval in Japan of a stem cell-based Parkinson's disease treatment, it announced on Tuesday, looking to ease the motor symptoms of sufferers and help push the country's stem cell treatment implementation forward.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store